Search
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact

There are more than 3 million people in the United States with IBD.

There are more than 3 million people in the United States with IBD.

Our Company

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with GI and liver diseases.

Latest News
November 14, 2022

Metacrine Reports Third-Quarter 2022 Results

September 06, 2022

Equillium to Acquire Metacrine in All-Stock Transaction

Programs

Our most advanced program targets the farnesoid X receptor (FXR) which is central to modulating GI and liver diseases.

© 2022 Metacrine   |   4225 Executive Square, Suite 600, San Diego, CA 92037
  • Our Company
    ▼
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    ▼
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    ▼
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      ▼
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      ▼
      • Sec Filings
    • Investor Resources
      ▼
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact